Key result
WCD successfully converts all life-threatening ventricular arrhythmias in the ~1% of pediatric patients receiving appropriate shocks.
Why the study?
Certain pediatric patients are at risk for sudden cardiac death and the effectiveness, safety, and compliance of the wearable cardioverter-defibrillator in this population needed evaluation.
Is the wearable cardioverter-defibrillator (WCD) safe, effective, and complied with in pediatric patients at risk for sudden cardiac death?
Cohort
Yes
Is the wearable cardioverter-defibrillator (WCD) safe, effective, and complied with in pediatric patients at risk for sudden cardiac death?
The wearable cardioverter-defibrillator is a safe and effective bridge therapy with adequate compliance for treating life-threatening ventricular arrhythmias in pediatric patients.
No takes yet. Share an insight, caveat, or question.
Supports WCD consideration as bridge in pediatric SCD risk; leaves open need for RCTs to confirm efficacy.
Spar et al. (2018) conducted a cohort in Risk for sudden cardiac death. Wearable cardioverter-defibrillator (WCD) was evaluated on Appropriate therapy for life-threatening ventricular arrhythmias. The wearable cardioverter-defibrillator provided appropriate shock therapy to 1.3% of pediatric patients, successfully converting all episodes of life-threatening ventricular arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: